Information de reference pour ce titreAccession Number: | 00126334-201904010-00013.
|
Author: | Davis, Nicole L. PhD, MPH a; Corbett, Amanda PharmD, BCPS, FCCP b; Kaullen, Josh PharmD b; Nelson, Julie A. E. PhD c; Chasela, Charles S. PhD d; Sichali, Dorothy BSc e; Hudgens, Michael G. PhD f; Miller, William C. MD, PhD, MPH g; Jamieson, Denise J. MD a; Kourtis, Athena P. MD, PhD, MPH a
|
Institution: | (a)Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA; (b)Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC; (c)Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; (d)Division of Epidemiology and Biostatistics, School of Public Health, University of Witwatersrand, Parktown, South Africa; (e)UNC Project Malawi, Lilongwe, Malawi; (f)Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC; and (g)Department of Epidemiology, Ohio State University, Columbus, OH.
|
Title: | |
Source: | JAIDS Journal of Acquired Immune Deficiency Syndromes. 80(4):467-473, April 1, 2019.
|
Abstract: | Background: Concentration of antiretroviral (ARV) drug found in plasma, and amounts of drug excreted into breastmilk, may affect HIV viral load and potentially perinatal HIV transmission.
Methods: In this cohort study with 2-phase sampling, we included mothers randomized to postpartum maternal ARVs or daily infant nevirapine during 28 weeks of breastfeeding in the Breastfeeding, Antiretrovirals, and Nutrition study. Among these, we included all mothers who transmitted HIV to their infants between 2 and 28 weeks and 15% of mothers who did not (n = 27 and 227, respectively). Spearman correlation coefficients (r2) were used to assess the correlation between maternal plasma and breastmilk ARV concentration. Associations between the median effective drug concentration (EC50) and detectable maternal viral load (plasma: >40 copies per milliliter, breastmilk: >56 copies per milliliter) were assessed using mixed-effects models. Cox models were used to estimate the association between maternal or infant plasma drug concentration and breastmilk HIV transmission from 2 to 28 weeks.
Results: All ARV compounds exhibited substantial correlations between maternal plasma and breastmilk concentrations (r2: 0.85-0.98, P-value <0.0001). Having plasma drug concentration above the EC50 was associated with lower odds of having detectable HIV RNA [maternal plasma odds ratio (OR) 0.64, 95% confidence interval (CI): 0.45 to 0.91; breastmilk OR 0.22, 95% CI: 0.14 to 0.35] and a reduced rate of breastmilk HIV transmission (hazard ratio 0.40, 95% CI: 0.18 to 0.93). Having breastmilk drug concentration above the EC50 was also associated with lower odds of having detectable maternal HIV RNA (plasma OR 0.62, 95% CI: 0.45 to 0.85; breastmilk OR 0.42, 95% CI: 0.29 to 0.59).
Conclusions: Ensuring adequate drug concentration is important for viral suppression and preventing breastmilk HIV transmission.
Copyright (C) 2019 Wolters Kluwer Health, Inc. All rights reserved.
|
Author Keywords: | antiretroviral therapy; breastmilk; HIV; perinatal transmission; pharmacokinetics; viral load.
|
References: | 1. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341:394-402.
2. Corbett AH. Antiretroviral Pharmacology in breast milk. In: Kourtis PA, Bulterys M, eds. Human Immunodeficiency Virus Type 1 (HIV-1) and Breastfeeding: Science, Research Advances, and Policy. New York, NY: Springer New York; 2012:109-118.
3. Salazar-Gonzalez JF, Salazar MG, Learn GH, et al. Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J Virol. 2011;85:2751-2763.
4. Fiscus SA, Aldrovandi GM. Virologic determinants of breast milk transmission of HIV-1. Adv Exp Med Biol. 2012;743:69-80.
5. Breslow NE, Lumley T, Ballantyne CM, et al. Using the whole cohort in the analysis of case-cohort data. Am J Epidemiol. 2009;169:1398-1405.
6. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362:2271-2281.
7. Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet 2012;379:2449-2458.
8. van der Horst C, Chasela C, Ahmed Y, et al. Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemp Clin Trials. 2009;30:24-33.
9. Rezk NL, White N, Bridges AS, et al. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit. 2008;30:611.
10. Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie. In Association for Quality Assessment in TDM and Clinical Toxicology; A section of the Dutch Foundation for Quality Assessment in Medical Laboratories: Available at: http://www.kkgt.nl- ouverture dans une nouvelle fenêtre. Accessed March 17, 2014.
11. National Institute of Allergy and Infectious Diseases. Clinical Pharmacology Quality Assurance Antiretroviral Proficiency Testing Program. In: AIDS Do. Available at: http://www.fstrf.org- ouverture dans une nouvelle fenêtre. Accessed March 17, 2014.
12. Viramune (Nevirapine) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2017.
13. Kaletra (Lopinavir and Ritonavir) [package insert]. North Chicago, IL: AbbVie Inc.; 2016.
14. Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother. 2001;45:1086-1093.
15. Breslow NE, Lumley T, Ballantyne CM, et al. Improved Horvitz-Thompson estimation of model parameters from two-phase stratified samples: applications in Epidemiology. Stat Biosci. 2009;1:32.
16. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10:37-48.
17. Davis NL, Miller WC, Hudgens MG, et al. Adherence to extended postpartum antiretrovirals is associated with decreased breast milk HIV-1 transmission. AIDS. 2014;28:2739-2749.
18. Davis NL, Miller WC, Hudgens MG, et al. Maternal and breastmilk viral load: impacts of adherence on peripartum HIV infections averted-the breastfeeding, antiretrovirals, and nutrition study. J Acquir Immune Defic Syndr. 2016;73:572-580.
19. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis. 2005;192:720-727.
20. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2009;53:1170-1176.
21. Corbett AH, Kayira D, White NR, et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post partum: results of the BAN Study. Antivir Ther. 2014;19:587-595.
22. Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol. 2006;2:947-960.
23. Riant P, Urien S, Albengres E, et al. High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochem Pharmacol. 1986;35:4579-4581.
|
Language: | English.
|
Document Type: | Clinical Science.
|
Journal Subset: | Nursing. Clinical Medicine. Health Professions.
|
ISSN: | 1525-4135
|
DOI Number: | https://dx.doi.org/10.1097/QAI.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|